Vistagen Therapeutics (VTGN) Free Cash Flow (2016 - 2025)
Vistagen Therapeutics (VTGN) has disclosed Free Cash Flow for 15 consecutive years, with -$17.7 million as the latest value for Q4 2025.
- Quarterly Free Cash Flow fell 70.1% to -$17.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$60.3 million through Dec 2025, down 54.21% year-over-year, with the annual reading at -$42.1 million for FY2025, 62.91% down from the prior year.
- Free Cash Flow hit -$17.7 million in Q4 2025 for Vistagen Therapeutics, down from -$13.9 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$4.8 million in Q4 2023 to a low of -$18.8 million in Q2 2025.
- Historically, Free Cash Flow has averaged -$11.2 million across 5 years, with a median of -$10.6 million in 2024.
- Biggest five-year swings in Free Cash Flow: crashed 837.16% in 2021 and later skyrocketed 62.18% in 2023.
- Year by year, Free Cash Flow stood at -$12.0 million in 2021, then rose by 19.19% to -$9.7 million in 2022, then soared by 51.05% to -$4.8 million in 2023, then tumbled by 117.9% to -$10.4 million in 2024, then tumbled by 70.1% to -$17.7 million in 2025.
- Business Quant data shows Free Cash Flow for VTGN at -$17.7 million in Q4 2025, -$13.9 million in Q3 2025, and -$18.8 million in Q2 2025.